Head to Head Survey: Arch Therapeutics (OTCMKTS:ARTH) & Beta Bionics (NASDAQ:BBNX)

Arch Therapeutics (OTCMKTS:ARTH) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Earnings and Valuation

This table compares Arch Therapeutics and Beta Bionics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arch Therapeutics	$80,000.00	10.79	-$6.98 million	N/A	N/A
Beta Bionics	$53.03 million	11.35	N/A	N/A	N/A

Beta Bionics has higher revenue and earnings than Arch Therapeutics.

Institutional and Insider Ownership

6.9% of Arch Therapeutics shares are owned by institutional investors. 4.5% of Arch Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Arch Therapeutics and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arch Therapeutics	-8,257.70%	N/A	-730.22%
Beta Bionics	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Arch Therapeutics and Beta Bionics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arch Therapeutics	0	0	0	0	0.00
Beta Bionics	0	3	5	1	2.78

Beta Bionics has a consensus target price of $24.83, indicating a potential upside of 76.88%. Given Beta Bionics’ stronger consensus rating and higher possible upside, analysts clearly believe Beta Bionics is more favorable than Arch Therapeutics.

Summary

Beta Bionics beats Arch Therapeutics on 8 of the 10 factors compared between the two stocks.

About Arch Therapeutics

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.